Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GSK PLC |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1,432.6 GBX | -0.51% | +0.93% | -0.35% | |
| 05:15pm | European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading | MT |
| 01:56pm | THG backer Kelso pushes for demerger to trim "inherent" valuation gap | AN |
ETFs positioned on GSK plc
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.37% | 19 M€ | +1.96% | ||
| 10.37% | 5 M€ | -3.66% | - | |
| 5.80% | 106 M€ | +1.40% | ||
| 5.80% | 34 M€ | -1.25% | - | |
| 5.07% | 982 M€ | +4.24% | ||
| 5.07% | 24 M€ | -.--% | ||
| 5.07% | 7 M€ | -3.16% | ||
| 4.86% | 136 M€ | +7.93% | ||
| 4.47% | 644 M€ | +4.50% | ||
| 4.45% | 492 M€ | +1.05% | ||
| 4.33% | 38 M€ | +5.82% | - | |
| 4.23% | 635 M€ | -.--% | ||
| 4.21% | 680 M€ | +5.01% | - | |
| 4.16% | 39 M€ | +6.77% | - | |
| 4.07% | 521 M€ | +9.29% | - | |
| 3.96% | 11 M€ | +0.22% | ||
| 3.81% | 75 M€ | +12.03% | ||
| 3.81% | 61 M€ | +12.00% | ||
| 3.80% | 1,633 M€ | +13.89% | - | |
| 3.73% | 11 M€ | +10.66% | ||
| 3.44% | 48 M€ | +10.95% | ||
| 3.44% | 1 M€ | +10.24% | - | |
| 3.17% | 107 M€ | +3.78% | - | |
| 3.17% | 127 M€ | -.--% | ||
| 3.17% | 2,408 M€ | +5.85% | - | |
| 3.17% | 11 M€ | +0.83% | - | |
| 3.16% | 79 M€ | +1.16% | ||
| 3.16% | 47 M€ | +0.67% | ||
| 3.16% | 42 M€ | +0.48% | - | |
| 3.16% | 1,792 M€ | -.--% | ||
| 3.16% | 61 M€ | 0.00% | - | |
| 3.16% | 21 M€ | +4.08% | ||
| 3.15% | 26 M€ | +9.53% | - | |
| 3.01% | 49 M€ | +4.54% | - | |
| 2.94% | 550 M€ | +4.63% | ||
| 2.94% | 55 M€ | +7.98% | - | |
| 2.94% | 71 M€ | +6.71% | - | |
| 2.90% | 6 M€ | +13.62% | - | |
| 2.90% | 22 M€ | +6.65% | ||
| 2.90% | 81 M€ | +7.12% | - | |
| 2.90% | 75 M€ | -.--% | - |
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
Sector
Pharmaceuticals
Calendar
2024-01-07
- JPMorgan Healthcare Conference
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
14.4GBP
Average target price
17.27GBP
Spread / Average Target
+19.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.35% | 73 892 M $ | |
| +60.14% | 530 B $ | |
| +42.05% | 438 B $ | |
| -11.74% | 377 B $ | |
| -5.78% | 268 B $ | |
| -8.46% | 258 B $ | |
| -14.13% | 230 B $ | |
| +0.79% | 200 B $ | |
| -9.98% | 198 B $ | |
| -43.82% | 163 B $ |
- Stock
- Equities
- Stock GSK plc - London Stock Exchange
- Funds and ETFs GSK plc
